NCT02263976View on ClinicalTrials.gov

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

June 30, 2004

Conditions
Healthy
Interventions
DRUG

BEA 2180 BR

DRUG

Placebo

DEVICE

Respimat® A 4

DRUG

Methacholine Chloride

methacholine challenge test

DRUG

Spiriva

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY